A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress) Meeting Abstract
| Authors: | Pennell, N. A.; Wirth, L. J.; Gainor, J. F.; Rotow, J. K.; Johnson, M. L.; Bauer, T. M.; Kroiss, M.; Sukrithan, V.; Kang, H.; Worden, F. P.; Bestvina, C. M.; Hadoux, J.; Cassier, P. A.; Italiano, A.; Wolf, J.; Brose, M. S.; Avsar, E.; Axelson, M. D.; Subbiah, V.; Drilon, A. E. |
| Abstract Title: | A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680305110 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS8595 |
| Notes: | Meeting Abstract: TPS8595 -- Meeting also held virtually -- Source: Wos |
